Last reviewed · How we verify
NCT02956148: LONGPDE10
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
EARLY_PHASE1 trial testing Radioligand [18F]MNI-659 in Huntington's Disease in 45 participants. Completed in 5 October 2017.
5 October 2017
Quick facts
| Lead sponsor | CHDI Foundation, Inc. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 45 |
| Start date | 6 September 2015 |
| Primary completion | 5 October 2017 |
| Estimated completion | 5 October 2017 |
| Sites | 7 locations across Denmark, Netherlands, Sweden, Norway |
Drugs / interventions tested
- Radioligand [18F]MNI-659
Conditions studied
- Huntington's Disease — all drugs for Huntington's Disease →
Sponsor
CHDI Foundation, Inc.
Who can join
Adults 18 to 73, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand \[18F\]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, et al · · 2020 · cited 25× · PMID 31967355 · DOI 10.1002/mds.27963 -
Bridging Huntington's disease research with big data science: Harmonized neuroimaging datasets from multiple studies.
Pustina D, Das S, Rozelle D, Johnson HJ, et al · · 2024 · PMID 40800273 · DOI 10.1162/imag_a_00395
Verify or expand the search:
- PubMed search for NCT02956148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Huntington's Disease
Currently open trials in the same condition.
- NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
- NCT06585449 — A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease · Phase 1 · recruiting
- NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting
Other CHDI Foundation, Inc. trials
Trials by the same sponsor.
- NCT03810898 — iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 · EARLY_PHASE1 · terminated
- NCT03628235 — HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States · completed
- NCT03709173 — FuRST 2.0 Cognitive Pre-testing - Round 2 · completed
- NCT02881931 — FuRST 2.0 Cognitive Pre-Testing · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02956148 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CHDI Foundation, Inc.
- Last refreshed: 10 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02956148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing